ABBV Q3 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

AbbVie posted a convincing third-quarter beat, reporting adjusted EPS of $1.86 against a consensus estimate of $1.78, a 4.23% positive surprise, while net revenues of $15.78 billion topped the $15.58 billion estimate by 1.23% and climbed 9.1% year ov… Read more AbbVie posted a convincing third-quarter beat, reporting adjusted EPS of $1.86 against a consensus estimate of $1.78, a 4.23% positive surprise, while net revenues of $15.78 billion topped the $15.58 billion estimate by 1.23% and climbed 9.1% year over year. The headline driver was unmistakably the immunology franchise, which generated $7.88 billion in revenue with Skyrizi surging 46.8% to $4.71 billion and Rinvoq advancing 35.3% to $2.18 billion, more than compensating for Humira's continued biosimilar-driven erosion to $993 million. Neuroscience added further momentum, growing 20.2% to $2.84 billion across a broad set of contributors. The quarter was not without complexity; a $2.68 billion acquired IPR&D charge tied largely to the Capstan Therapeutics acquisition weighed heavily on GAAP results. Still, management expressed enough confidence in the underlying business to raise full-year 2025 adjusted EPS guidance to $10.61 to $10.65, while also announcing a 5.5% dividend increase to $1.73 per share quarterly.